phenprocoumon has been researched along with Kidney-Failure--Chronic* in 7 studies
1 review(s) available for phenprocoumon and Kidney-Failure--Chronic
Article | Year |
---|---|
Effect of diseases on response to vitamin K antagonists.
The purpose of this review article is to summarize the literature on diseases that are documented to have an effect on response to warfarin and other VKAs.. We searched the English literature from 1946 to September 2015 via PubMed, EMBASE, and Scopus for the effect of diseases on response vitamin K antagonists including warfarin, acenocoumarol, phenprocoumon, and fluindione.. Among many factors modifying response to VKAs, several disease states are clinically relevant. Liver disease, hyperthyroidism, and CKD are well documented to increase response to VKAs. Decompensated heart failure, fever, and diarrhea may also elevate response to VKAs, but more study is needed. Hypothyroidism is associated with decreased effect of VKAs, and obese patients will likely require higher initial doses of VKAs.. In order to minimize risks with VKAs while ensuring efficacy, clinicians must be aware of the effect of disease states when prescribing these oral anticoagulants. Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Cardiovascular Diseases; Diarrhea; Fibrinolytic Agents; Heart Failure; Humans; Hyperthyroidism; Kidney Failure, Chronic; Liver Diseases; Obesity; Phenindione; Phenprocoumon; Vitamin K; Warfarin | 2016 |
1 trial(s) available for phenprocoumon and Kidney-Failure--Chronic
Article | Year |
---|---|
The effect of oral anticoagulation on clotting during hemodialysis.
Between 5% and 10% of hemodialysis patients are treated with oral anticoagulants. It is currently unknown whether additional anticoagulation with heparin or low-molecular-weight heparin (LMWH) is needed to prevent clotting during hemodialysis.. In this prospective, randomized, cross-over study 10 patients treated with oral anticoagulants (phenprocoumon) received either no additional anticoagulation or low dose dalteparin (bolus of 40 IU/kg body weight) before dialysis. Efficacy of hemodialysis was measured by normalized weekly Kt/V and urea reduction rate (URR). Thrombus formation was evaluated by measurement of D-dimer and inspection of air traps and dialyser.. The median international normalized ratio (INR) did not differ between both observation periods (phenprocoumon 2.2(2 to 3) vs. dalteparin 2.1(2 to 2.9). The anti-Xa level in dalteparin patients was 0.33 (0.27 to 0.38) IU/mL after 2 hours and 0.16 (0.03 to 0.23) IU/mL after 4 hours of hemodialysis. The median increase of D-dimer was significantly higher in patients without additional dalteparin therapy during hemodialysis (DeltaD-dimer 0.23 microg/mL vs. 0.03 mug/mL) (P= 0.0004). Complete thrombosis of the dialyser membrane occurred in one patient in the phenprocoumon group but in none with combined treatment. The extent of thrombosis in the arterial and venous air trap and dialyser was significantly less in patients with additional dalteparin therapy (P= 0.0014, P= 0.0002, and P= 0.0005, respectively). Weekly Kt/V and URR was similar in both groups.. Standard oral anticoagulation with an INR between 2 and 3 is insufficient to prevent clotting during hemodialysis. Additional low dose anticoagulation with a LMWH or heparin is necessary to facilitate treatment. Topics: Administration, Oral; Aged; Anticoagulants; Blood Coagulation; Cross-Over Studies; Dalteparin; Drug Therapy, Combination; Female; Fibrin Fibrinogen Degradation Products; Heparin, Low-Molecular-Weight; Humans; Kidney Failure, Chronic; Male; Middle Aged; Phenprocoumon; Prospective Studies; Renal Dialysis; Thrombosis | 2005 |
5 other study(ies) available for phenprocoumon and Kidney-Failure--Chronic
Article | Year |
---|---|
Phenprocoumon based anticoagulation is an underestimated factor in the pathogenesis of calciphylaxis.
Calciphylaxis is a life threatening complication in renal patients. Of great importance is the identification of concomitant factors for calciphylaxis. Due to the variability of clinical presentation the evaluation of such factors may be obscured when calciphylaxis diagnosis is based just on clinical features. We aimed to characterize associated factors only in patients with calciphylaxis proven by histomorphological parameters in addition to clinical presentation.. In a single center retrospective study we analyzed 15 patients in an 8 year period from 2008 to 2016. Only patients with clinical features and histomorphological proof of calciphylaxis were included. Criteria for histological diagnosis of calciphylaxis were intimal hyperplasia, micro thrombi or von Kossa stain positive media calcification.. The mean age of patients was 64.8 years. Nine patients (60%) were female; 12 (80%) were obese with a Body-Mass-Index (BMI) > 30 kg/m. The evaluation of biopsy proven calciphylaxis demonstrates that especially treatment with vitamin K antagonists and liver dysfunction are most important concomitant factors in development of calciphylaxis. As progression and development of calciphylaxis are chronic rather than acute processes, early use of DOACs instead of VKA might be beneficial and reduce the incidence of calciphylaxis. Topics: Anticoagulants; Biopsy; Calciphylaxis; Female; Germany; Humans; Incidence; Kidney Failure, Chronic; Liver Diseases; Male; Microvessels; Middle Aged; Mortality; Patient Selection; Phenprocoumon; Retrospective Studies; Risk Factors; Thrombosis; Vascular Calcification | 2019 |
[Emergency checklist: Upper gastrointestinal bleeding].
Topics: Aged, 80 and over; Atrial Fibrillation; Checklist; Diagnosis, Differential; Emergencies; Female; Gastritis; Gastrointestinal Hemorrhage; Gastroscopy; Humans; Kidney Failure, Chronic; Phenprocoumon | 2015 |
Calciphylaxis.
Topics: Anticoagulants; Calciphylaxis; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Leg; Male; Middle Aged; Phenprocoumon; Radiography; Renal Dialysis; Skin Ulcer | 2014 |
Cohort study on the quality of oral anticoagulation therapy in chronic haemodialysis patients treated with phenprocoumon.
Few studies have been published on the control of oral anticoagulation treatment in end stage renal disease (ESRD).. To analyse the quality of oral anticoagulation treatment control in ESRD patients treated with phenprocoumon we conducted a cohort study including all patients on chronic haemodialysis at a reference date. Data were collected retrospectively for 12 months and prospectively for 12 months preceding following the reference date. Endpoint was the percentage of INR in target range.. 30 (27%) of 111 patients received oral anticoagulation treatment. The median frequency of INR measurements was every 6.5 days (range 1-16). In median 54% (range 17-74%) and 49% (range 21-65%) of INR measurements were within, 17% (range 0-45%) and 19% (range 4-56%) were above and 27% (range 8-83%) and 33% (range 9-57%) were below the target range in the retrospective and prospective dataset, respectively. The percentage of INR measurements within target range was significantly higher in patients with a target range width of 1.0 than in patients with a target range width of 0.5 (p = 0.04). There was no difference in the number of bleedings or thromboembolic events in patients with and without oral anticoagulation treatment.. In our ESRD cohort, the percentage of INR in target range in patients treated with phenprocoumon seems comparable with published data on warfarin and data in non-ESRD populations. However, this finding has to be confirmed in larger studies powered for analysing the factors influencing INR control and the impact of INR control on bleeding and thromboembolic events in ESRD patients treated with phenprocoumon. Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Drug Administration Schedule; Drug Monitoring; Female; Humans; International Normalized Ratio; Kidney Failure, Chronic; Male; Middle Aged; Phenprocoumon; Prospective Studies; Quality of Health Care; Renal Dialysis; Retrospective Studies; Thromboembolism; Treatment Outcome | 2013 |
[Peculiarities in the treatment of dialysis patients using phenprocoumon (Marcumar)].
Topics: Coumarins; Humans; Kidney Failure, Chronic; Phenprocoumon; Renal Dialysis; Thrombosis | 1975 |